Cargando…

Nanoparticles modified by polydopamine: Working as “drug” carriers

Inspired by the mechanism of mussel adhesion, polydopamine (PDA), a versatile polymer for surface modification has been discovered. Owing to its unique properties like extraordinary adhesiveness, excellent biocompatibility, mild synthesis requirements, as well as distinctive drug loading approach, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Anting, Wang, Yitong, Lin, Kaili, Jiang, Lingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170807/
https://www.ncbi.nlm.nih.gov/pubmed/32322763
http://dx.doi.org/10.1016/j.bioactmat.2020.04.003
_version_ 1783523948923715584
author Jin, Anting
Wang, Yitong
Lin, Kaili
Jiang, Lingyong
author_facet Jin, Anting
Wang, Yitong
Lin, Kaili
Jiang, Lingyong
author_sort Jin, Anting
collection PubMed
description Inspired by the mechanism of mussel adhesion, polydopamine (PDA), a versatile polymer for surface modification has been discovered. Owing to its unique properties like extraordinary adhesiveness, excellent biocompatibility, mild synthesis requirements, as well as distinctive drug loading approach, strong photothermal conversion capacity and reactive oxygen species (ROS) scavenging facility, various PDA-modified nanoparticles have been desired as drug carriers. These nanoparticles with diverse nanostructures are exploited in multifunctions, consisting of targeting, imaging, chemical treatment (CT), photodynamic therapy (PDT), photothermal therapy (PTT), tissue regeneration ability, therefore have attracted great attentions in plenty biomedical applications. Herein, recent progress of PDA-modified nanoparticle drug carriers in cancer therapy, antibiosis, prevention of inflammation, theranostics, vaccine delivery and adjuvant, tissue repair and implant materials are reviewed, including preparation of PDA-modified nanoparticle drug carriers with various nanostructures and their drug loading strategies, basic roles of PDA surface modification, etc. The advantages of PDA modification in overcoming the existing limitations of cancer therapy, antibiosis, tissue repair and the developing trends in the future of PDA-modified nanoparticle drug carriers are also discussed.
format Online
Article
Text
id pubmed-7170807
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-71708072020-04-22 Nanoparticles modified by polydopamine: Working as “drug” carriers Jin, Anting Wang, Yitong Lin, Kaili Jiang, Lingyong Bioact Mater Article Inspired by the mechanism of mussel adhesion, polydopamine (PDA), a versatile polymer for surface modification has been discovered. Owing to its unique properties like extraordinary adhesiveness, excellent biocompatibility, mild synthesis requirements, as well as distinctive drug loading approach, strong photothermal conversion capacity and reactive oxygen species (ROS) scavenging facility, various PDA-modified nanoparticles have been desired as drug carriers. These nanoparticles with diverse nanostructures are exploited in multifunctions, consisting of targeting, imaging, chemical treatment (CT), photodynamic therapy (PDT), photothermal therapy (PTT), tissue regeneration ability, therefore have attracted great attentions in plenty biomedical applications. Herein, recent progress of PDA-modified nanoparticle drug carriers in cancer therapy, antibiosis, prevention of inflammation, theranostics, vaccine delivery and adjuvant, tissue repair and implant materials are reviewed, including preparation of PDA-modified nanoparticle drug carriers with various nanostructures and their drug loading strategies, basic roles of PDA surface modification, etc. The advantages of PDA modification in overcoming the existing limitations of cancer therapy, antibiosis, tissue repair and the developing trends in the future of PDA-modified nanoparticle drug carriers are also discussed. KeAi Publishing 2020-04-18 /pmc/articles/PMC7170807/ /pubmed/32322763 http://dx.doi.org/10.1016/j.bioactmat.2020.04.003 Text en © 2020 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Jin, Anting
Wang, Yitong
Lin, Kaili
Jiang, Lingyong
Nanoparticles modified by polydopamine: Working as “drug” carriers
title Nanoparticles modified by polydopamine: Working as “drug” carriers
title_full Nanoparticles modified by polydopamine: Working as “drug” carriers
title_fullStr Nanoparticles modified by polydopamine: Working as “drug” carriers
title_full_unstemmed Nanoparticles modified by polydopamine: Working as “drug” carriers
title_short Nanoparticles modified by polydopamine: Working as “drug” carriers
title_sort nanoparticles modified by polydopamine: working as “drug” carriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170807/
https://www.ncbi.nlm.nih.gov/pubmed/32322763
http://dx.doi.org/10.1016/j.bioactmat.2020.04.003
work_keys_str_mv AT jinanting nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers
AT wangyitong nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers
AT linkaili nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers
AT jianglingyong nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers